Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer

Advances in Biological Regulation(2018)10.1016/j.jbior.2017.11.007Source: DataRank Database

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer is a research paper published in Advances in Biological Regulation (2018). On theSindex it has a DataRank of 0.782. It has been cited 183 times.

N/A

0.782DataRank · unranked

Scored on demand from live citation data

183 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 5.05)OA: closedTopics (33)Linked Datasets (22)DataCite Reuse (22)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.782

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Omar Elaskalani,Aikaterini Emmanouilidi ORCID,Minkyoung Kim ORCID,Norbaini Binti Abdol Razak,Pat Metharom

Live enrichment

PubMed:29221990 OpenAlex:https://openalex.org/W2768095276

Australian Rotary Health

PanKind, The Australian Pancreatic Cancer Foundation

Curtin University, Malaysia

Curtin Health Innovation Research Institute, Curtin University

FWCI

5.05

Citation Percentile

1.0%

Citation Trend

2014

2018

2019

2020

2021

2022

2023

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S2212492617301768?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2212492617301768?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jbior.2017.11.007

repositoryhttps://pubmed.ncbi.nlm.nih.gov/29221990

repositoryhttp://hdl.handle.net/20.500.11937/62659

Fields of Study

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentRenal cell carcinoma treatmentAnimalsDeoxycytidineDrug Resistance, NeoplasmFluorouracilHumansPancreatic NeoplasmsGemcitabine

MeSH Terms

GemcitabineAnimalsDeoxycytidineFluorouracilHumansPancreatic NeoplasmsDrug Resistance, Neoplasm

Keywords

GemcitabineFOLFIRINOXPancreatic cancerIrinotecanMedicineOxaliplatinOncologyChemotherapyCancerPaclitaxelInternal medicineCancer researchImmunotherapyColorectal cancerChemoresistanceTumour Microenvironment

Additional file 1 of CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

10.6084/m9.figshare.20459990.v1figshare

Additional file 1 of CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

10.6084/m9.figshare.20459990figshare

Additional file 1 of A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

10.6084/m9.figshare.26597750.v1figshare

Additional file 1 of A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

10.6084/m9.figshare.26597750figshare

Additional file 9 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644360.v1figshare

Additional file 9 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644360figshare

Additional file 7 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644354.v1figshare

Additional file 8 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644357.v1figshare

Additional file 8 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644357figshare

Additional file 5 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644348figshare

Additional file 7 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644354figshare

Additional file 3 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644342.v1figshare

Additional file 4 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644345.v1figshare

Additional file 4 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644345figshare

Additional file 3 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644342figshare

Additional file 5 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644348.v1figshare

Additional file 6 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644351figshare

Additional file 6 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.26644351.v1figshare

Additional file 1 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.24630276.v1figshare

Additional file 1 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer

10.6084/m9.figshare.24630276figshare

Related Papers (8)

Prognostic impact of Charlson’s Age‐Comorbidity Index and other risk factors in patients with pancreatic cancer

European Journal of Cancer Care(2020)

co-cited

10.1111/ecc.13219

Estimated Projection of US Cancer Incidence and Death to 2040

Top 3%

6.8DataRank

JAMA Network Open(2021)

co-cited

10.1001/jamanetworkopen.2021.4708

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

N/A

1.3DataRank · unranked

New England Journal of Medicine(2011)

co-cited

10.1056/nejmoa1011923

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

N/A

1.5DataRank · unranked

European Journal of Cancer(2009)

co-cited

10.1016/j.ejca.2008.10.026

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

N/A

1.3DataRank · unranked

New England Journal of Medicine(2013)

co-cited

10.1056/nejmoa1304369

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

N/A

1.6DataRank · unranked

Journal of Biomedical Informatics(2009)

co-cited

10.1016/j.jbi.2008.08.010

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N/A

1.5DataRank · unranked

JNCI Journal of the National Cancer Institute(1993)

co-cited

10.1093/jnci/85.5.365

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients

N/A

0.693DataRank · unranked

Journal of Geriatric Oncology(2023)

co-cited

10.1016/j.jgo.2023.101474

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer

FAIR Checklist

DataRank Breakdown

Authors (7)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (22)

Related Papers (8)